Statement of Deviation or Variation of Funds under Regulation 32 of SEBI (LODR) Regulations, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd has filed a quarterly compliance statement confirming that there is no deviation or variation in the use of funds raised through a preferential allotment. The company had raised Rs. 21.80 crore on 4 February 2024 by issuing 1,36,28,750 equity shares to strategic non-promoter investors. The funds were earmarked for working capital needs, acquisition of business/factory/office/machinery, and general corporate purposes. The statement, reviewed by the Audit Committee and approved by the Board on 30 May 2025, confirms that the proceeds are being utilised in line with the originally stated objectives for the quarter ended 31 March 2025.
This is a routine regulatory filing and carries no material impact on shareholders. It simply reaffirms that the company is using the Rs. 21.80 crore raised from the preferential issue as originally planned, which is a neutral to mildly positive sign of fund-use discipline.